Regeneron Pharmaceuticals (NasdaqGS:REGN) received FDA approval for extended EYLEA HD dosing intervals for wet age-related macular degeneration and diabetic macular edema. The updated label allows ...
Earlier this month at the J.P. Morgan Healthcare Conference, Regeneron got its Eylea sales news out of the way. As has been the case for several quarters, as sales of Eylea HD have increased, those of ...
Hosted on MSN
Regeneron’s new growth engine is starting to show – but core Eylea weakness weighs on REGN stock
・Non-GAAP earnings slipped 5% to $11.44 per share but still came in ahead of analysts’ forecasts of $10.74. ・Sales of the Eylea declined amid competitive pressure and a shift of patients to the ...
Regeneron Pharmaceuticals REGN announced that the FDA has approved extending dosing intervals of up to every 20 weeks for ...
We recently compiled a list of the 20 Most Profitable Stocks of the Last 20 Years. Regeneron Pharmaceuticals, Inc. is among the most profitable stocks. TheFly reported on January 22 that Evercore ISI ...
Regeneron Pharmaceuticals REGN put up a decent performance for the fourth quarter of 2025 and full-year 2025 (reported last month) with overall revenues rising despite a continued decline in sales of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results